Michael Halpin, Chief Operating Officer of Vericel Corporation (NASDAQ:VCEL), reported the sale of 10,000 shares of Common Stock for a transaction value of approximately $402,000 on June 18, 2026, as disclosed in a SEC Form 4 filing.
Transaction summary
Transaction value based on SEC Form 4 weighted average purchase price ($40.24); post-transaction value based on June 18, 2026 market close.
Key questions
-
How does this transaction compare to Halpin’s historical sale sizes?
The 10,000-share sale aligns with the range recorded over the past two years. -
What is the impact on Halpin’s overall equity exposure in Vericel?
While direct Common Stock holdings decreased to 16,248 shares, Halpin maintains 36,250 options outstanding, preserving a substantial economic interest that could be exercised for future share acquisition. -
What was the structure and motivation of the transaction?
This sale consisted of an option exercise immediately followed by an open-market disposition. -
Did the transaction occur at a premium or discount to recent market prices?
The weighted average sale price of around $40.24 per share closely tracked the market close of $40.10 on June 18, 2026, suggesting execution in line with prevailing market levels at the time of sale.
Company overview
Company snapshot
-
Vericel’s core products include MACI, an autologous cellularized scaffold for knee cartilage repair, and Epicel, a permanent skin replacement for severe burns; NexoBrid, a biological eschar removal product, is in the registration phase.
-
The company generates revenue through the commercialization of its proprietary cell-based therapies and related biologics, targeting critical needs in sports medicine and burn care.
-
Primary customers are hospitals, burn centers, and orthopedic clinics in the United States, with a focus on patients requiring advanced regenerative treatments for cartilage damage or severe burns.
Vericel Corporation operates as a commercial-stage biopharmaceutical company specializing in advanced cell therapies for sports medicine and burn care. With a focused product portfolio and established distribution in the U.S. hospital and specialty clinic markets, the company leverages proprietary technologies to address unmet medical needs. Its strategy centers on expanding the adoption of its FDA-approved therapies and advancing new indications to strengthen its competitive position in regenerative medicine.
